[ad_1]
MENLO PARK, Calif., June 10, 2019 (GLOBE NEWSWIRE) – Geron Corporation (Nasdaq: GERN) announced today that the company will be webcasting an event on June 25, 2019, featuring industry leaders. opinion (KOL) authors of the book imetelstat. The data will be presented at the 24th Annual Congress of the European Association of Hematology (EHA). The KOL will resume the presentations made at EHA and Geron's management team will provide an update on the progress made in achieving the company's goals for 2019, including the opening of the planned part of Phase 3 of IMerge for screening and registration in the summer of 2019. The KOL event will begin at 8:00 am ET.
Uwe Platzbecker, MD, Director of the Department of Medicine I – Hematology and Cell Therapy, Medical Center of the University of Leipzig, Leipzig, Germany, will review the efficacy and safety data presented at IMerge Phase 2 of IMerge, the clinical program in Phase 2/3. Imetelstat test in patients with low-risk myelodysplastic syndromes.
Rami Komrokji, MD, clinical director, principal investigator of the Department of Malignant Hematology, Moffitt Cancer Center, Tampa, Fla., Will review the badyzes presented at the EHA for the overall survival (OS) data of patients with Relapsed / refractory myelofibrosis (FM) treated with 9.4 mg / kg of imetelstat in the IMbark Phase 2 clinical trial, compared to real-world data (RWD) of patients with Closely matched MFs who discontinued treatment with a JAK inhibitor (JAKi) and who were then treated with the best available treatment.
A live audio broadcast of the event will be available on Geron's website, www.geron.com/investors/events. If you can not listen to the event live, an archived webcast of the event will be available on the Company's website for 30 days.
About Imetelstat
Imetelstat is a new telomerase inhibitor, the first in its clbad, which belongs exclusively to Geron and is currently being developed for the treatment of myeloid hematological malignancies. Early clinical data suggest that imetelstat could have disease modifying activity by suppressing the proliferation of malignant progenitor cell clones, which would allow for a potential recovery of normal hematopoiesis. Current clinical studies on imetelstat include a phase 2/3 trial, called IMerge, on low-risk myelodysplastic syndromes (MDS) and a phase 2 trial, called IMbark, on 2-to-high intermediate-level myelofibrosis. Imetelstat received the US Food and Drug Administration's Fast Track designation for the treatment of patients with transfusion-related anemia due to low-risk, non-reemulsive (5q), refractory or resistance-tolerant MDS. erythroid.
About Geron
Geron is an advanced clinical biopharmaceutical company focused on the development and potential commercialization of a first telomerase inhibitor, imetelstat, for the treatment of haematological myeloid malignancies. For more information on Geron, visit www.geron.com.
Use of forward-looking statements
Except for the historical information contained in this document, this press release contains forward-looking statements made pursuant to the provisions of the "Securities Act" of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that these statements include, without limitation, those concerning: (i) it is planned to open IMerge Phase 3 for screening and registration in the summer of 2019; ii) that the imetelstat may have an activity modifying the disease; and (iii) other statements that are not historical facts are forward-looking statements. These statements involve risks and uncertainties that may cause actual results to differ materially from those in these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties related to: (i) the fact that the Company overcomes all clinical, safety and operational, technical, scientific, manufacturing and regulatory Phase 3 opening planned part of IMerge for screening and registration in the summer of 2019; (ii) whether the regulatory authorities allow the further development of imetelstat in a timely manner or at all without clinical expectation; and (ii) if imetelstat demonstrates disease modifying activity. Additional information regarding the above risks and uncertainties, as well as additional risks, uncertainties and additional factors that could cause actual results to differ materially from those presented in the forward-looking statements, can be found in Geron's periodic reports filed with the Securities and Exchange Commission. Exchange Commission under the heading "Risk Factors". Including Geron's Quarterly Report on Form 10-Q for the three months ended March 31, 2019. Do not place undue reliance on forward-looking statements, which speak only as of the date on which they were made, as well as the facts and badumptions underlying the statement. Forward-looking statements may change. With the exception of what is required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances.
CONTACT:
Suzanne Messere
Investor Relations and Media
[email protected]
[email protected]
CG Capital
877-889-1972
Source link
